Dose adjustments to existing treatments
The effects of certain drugs can vary greatly based on dosage, making them ideal candidates for repurposing research. Methrotrexate was developed as a chemotherapy drug in the 1950s and has since been administered at a very high dose to cancer patients. At a low dose, and because of totally different mechanisms of the drug, it has become a standard of care for auto-immune diseases such as rheumatoid arthritis (1). Researchers have since ironed the drug’s alternative mechanisms through studies on juvenile idiopathic arthritis (2).
2. Bulatovic Calasan M., Vastert S.J., Scholman R.C., Verweij F., Klein M., Wulffraat N.M., Prakken B.J., and van Wijk F. (2015). Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis. Rheumatology Feb 2015. [Link here]